Jubilant Ingrevia has outlined a dual-track growth strategy centered on significant capital expenditure and potential large-scale acquisitions.
The specialty chemicals company plans to spend between ₹500 crore and ₹600 crore annually on capital projects to expand production capacity in nutrition and specialty chemicals.
Beyond organic expansion, management is actively weighing acquisitions valued at $500 million or more.
This commitment follows a period of intense investment, during which the firm deployed nearly ₹2,000 crore in capex over the previous three years.
Beyond organic expansion, management is actively weighing acquisitions valued at $500 million or more.
Chief Executive Officer and Managing Director Deepak Jain indicated that the company is evaluating targets that would bolster its portfolio in high-growth segments.
The move signals a shift toward inorganic growth as a primary lever for scaling operations, complementing the ongoing infrastructure build-out.